Last reviewed · How we verify
eye drop bromfenac 0.09%
At a glance
| Generic name | eye drop bromfenac 0.09% |
|---|---|
| Sponsor | Babasaheb Ambedkar Memorial Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery (NA)
- Bromfenac Versus Dexamethasone After Cataract Surgery (PHASE4)
- Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (PHASE4)
- Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (PHASE4)
- Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
- Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection. (PHASE4)
- Control of Pain in Intravitreal Injections Using Topical NSAIDs (PHASE4)
- Comparison of Treatments in Diabetic Macular Edema (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- eye drop bromfenac 0.09% CI brief — competitive landscape report
- eye drop bromfenac 0.09% updates RSS · CI watch RSS
- Babasaheb Ambedkar Memorial Hospital portfolio CI